Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.14 · Revenue $500000.00 · 4 analysts
Est. EPS $-0.15 · Revenue $2.69M · 4 analysts
Est. EPS $-0.46 · Revenue $2.30M · 5 analysts
Est. EPS $-0.13 · Revenue $7.37M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-118.8M | -23.9% | -7.9% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-101.1M | -13.4% | +9.5% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 14.7% | -5.6% | +22.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 11.85x | -13.7% | -24.8% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $253.4M | +19.1% | -13.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.53 vs -0.80 | +33.8% | -0.16 vs -0.14 | -11.5% |
| Revenue Surprise | $0 vs $1.4M | -100.0% | $0 vs $500000 | -100.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | Lutz Robert Matthew | officer: Chief Fin. & Operating Officer | Common Stock | A | 35,000 | — |
| Jul 15, 2026 | Lutz Robert Matthew | officer: Chief Fin. & Operating Officer | Stock Option (Right to Buy) | A | 70,000 | $5.81 |
| Jun 22, 2026 | Lowrance David L | officer: Chief Financial Officer | Common Stock | A | 87,650 | $3.35 |
| Jun 22, 2026 | Lowrance David L | officer: Chief Financial Officer | Common Stock | A | 218,750 | $1.51 |
| Jun 22, 2026 | Lowrance David L | officer: Chief Financial Officer | Common Stock | D | 53,387 | $5.50 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Matthew Pauls | Chairman & Chief Executive Officer | USD 975,000 | Male | 1971 | Active |
Yasmine Wasfi | Chief Medical Officer | USD 681,578 | — | — | Active |
David L. Lowrance | Chief Financial & Administrative Officer and Secretary | USD 665,625 | Male | 1968 | Active |
Robert Lutz | COO & CFO | USD 665,625 | Male | 1969 | Active |
Kate McCabe | Chief Legal Officer | — | Female | 1986 | Active |
Megan Carpenter | Chief People Officer | — | Female | — | Active |
Brian Robinson | Executive Vice President of Global Medical Affairs | — | — | — | Active |
Charles LaPree | Executive Vice President & Head of Global Regulatory Affairs | — | Male | — | Active |
Anne Erickson | Chief Business & Corporate Affairs Officer | — | Female | 1972 | Active |
Brian Maurer | Head of Clinical Operations | — | — | — | Active |
Siddharth J. Advant | Executive Vice President of Global Technical Operations | — | — | — | Active |
BlackRock Inc. acquired a new position in Savara Inc. (NASDAQ: SVRA) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 12,494,498 shares of the company's stock, valued at approximately $76,966,000. BlackRock Inc. owned approximately 6.10% of Savara at the end of
Algert Global LLC boosted its position in Savara Inc. (NASDAQ: SVRA) by 53.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,329,259 shares of the company's stock after purchasing an additional 464,645 shares during the quarter. Algert Global LLC
Deutsche Bank AG purchased a new position in Savara Inc. (NASDAQ: SVRA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 864,956 shares of the company's stock, valued at approximately $5,328,000. Deutsche Bank AG owned about 0.42% of Savara as of its
YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of.
YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company's common stock and restricted stock units (RSUs).
